NVO · Company research
9 upcoming catalysts · 0 phase 2+ trials on file
View Stock opens Yahoo Finance. Prices and performance charts are provided there.
Phase 3 starts: oral zenagamtide (Q3), SC zenagamtide CVOT and high-dose cagrilintide (Q4), expected in the second half of 2026 (no exact date yet). A company milestone for Novo Nordisk (Zenagamtide (amycretin); cagrilintide for Obesity / cardiovascular outcomes): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Novo Nordisk presents data on CagriSema for Obesity / weight management (1.0/1.0 and 1.7/1.7 mg doses) at a medical meeting in the second half of 2026 (no exact date yet). New numbers at a conference can move the stock as much as a formal announcement.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA is expected to decide in Q4 2026 (Oct–Dec) (no exact date yet) whether to approve Novo Nordisk’s CagriSema (cagrilintide + semaglutide) for Chronic weight management (obesity/overweight). Approval clears it for sale in the US; a rejection usually arrives as a letter listing what has to be fixed first.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA is expected to decide in Q4 2026 (Oct–Dec) (no exact date yet) whether to approve Novo Nordisk’s Ozempic pill (oral semaglutide 25 mg) for Type 2 diabetes. Approval clears it for sale in the US; a rejection usually arrives as a letter listing what has to be fixed first.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA is expected to decide in Q4 2026 (Oct–Dec) (no exact date yet) whether to approve Novo Nordisk’s Sogroya (somapacitan) for Short stature in Turner syndrome. Approval clears it for sale in the US; a rejection usually arrives as a letter listing what has to be fixed first.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Etavopivat US and EU submissions in sickle cell disease, expected in Q4 2026 (Oct–Dec) (no exact date yet). A company milestone for Novo Nordisk (Etavopivat for Sickle cell disease): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Novo Nordisk expects to report results from its Phase 3 study of Efruxifermin for MASH, fibrosis stage 1-4 in Q4 2026 (Oct–Dec) (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA is expected to decide in Q1 2027 (Jan–Mar) (no exact date yet) whether to approve Novo Nordisk’s Wegovy pill (oral semaglutide 25 mg) for MASH with F2-F3 fibrosis. Approval clears it for sale in the US; a rejection usually arrives as a letter listing what has to be fixed first.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Novo Nordisk expects European regulators to decide on Sogroya (somapacitan) for Short stature in Turner syndrome in the first half of 2027 (no exact date yet). An approval lets the company start selling it in that market.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA’s decision on Novo Nordisk’s Denecimig (Mim8, FVIIIa-mimetic bispecific) for Hemophilia A prophylaxis, with or without inhibitors was due on Sep 30, 2026. The outcome isn’t recorded here yet — the linked source has the latest.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
European regulators approved Novo Nordisk’s Denecimig (Mim8) for Hemophilia A prophylaxis in Q3 2026 (Jul–Sep). The company can now sell it in that market.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Novo Nordisk reported results from its Phase 3 study of Ziltivekimab for ASCVD with CKD and inflammation on Jul 31, 2026. The study missed its main goal.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Novo Nordisk presented data on CagriSema (cagrilintide/semaglutide 2.4/2.4 mg) for Type 2 diabetes at a medical meeting on Jun 7, 2026. The linked source has the details.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Novo Nordisk reported results from its Phase 3 study of Etavopivat for Sickle cell disease on Apr 20, 2026. The study met its main goal.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA approved Novo Nordisk’s Wegovy HD (semaglutide) 7.2 mg for Chronic weight management in adults with obesity on Mar 19, 2026. The company can now sell it in that market.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Novo Nordisk reported results from its Phase 3 study of semaglutide (Wegovy) for CV outcomes in obesity on Aug 8, 2023. The linked source has what the numbers showed.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Explore reported politician transactions and public investor statements connected to NVO.
View source-linked activity ↗No phase 2+ trials cached for this company.
No recent headlines on file.